Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta

Contributed by: Business Wire

Logo

Tags

Health

Clinical Trials

Research

Pharmaceutical

Science

Biotechnology

Ferring Pharmaceuticals

More Like This

Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin

Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927

First Patients Dosed in Debiopharm's Phase III Trial (LIBELULA) Investigating Debio 4326, a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera